Private Equity, Venture Capital Flows To Biotechnology Lowest Since 2019
In 2024, global private equity and venture capital transaction value and volume in biotechnology declined to their lowest ...
Biogen continues dealmaking buzz with Stoke Therapeutics
Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...